Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1675
This examiner grants 55% of resolved cases
Sarah Cooper Patterson serves in Tech Center 1600 and Art Unit 1675. The examiner has 38 resolved cases and an allowance rate of 55.3%. This 55.3% rate provides a baseline for the probability of success for applications in this unit. The median days to allowance is 1467, which indicates a longer prosecution timeline. These 38 resolved cases offer a focused look at the examiner's performance trends.
The interview lift is 59.5%, indicating that direct communication with the examiner is an effective strategy. This 59.5% lift suggests that an interview can improve the chances of reaching an allowance from the 55.3% baseline. Practitioners should prioritize requesting an interview to resolve outstanding issues. The 1467-day median pendency is a factor for applicants to manage their expectations. These metrics provide a clear roadmap for successful prosecution, emphasizing the benefit of engaging in a dialogue with the examiner in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17608890 | IRF2 AS A PROGNOSTIC BIOMARKER AND TARGET FOR AUGMENTING IMMUNOTHERAPY | Final Rejection | University of Massachusetts |
| 17639525 | METHODS OF TREATING KRAS MUTANT CANCERS | Non-Final OA | The Regents of the University of California |
| 17762980 | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES | Non-Final OA | The Regents of the University of Michigan |
| 17933052 | Interleukin-9 Signaling in Chimeric Antigen Receptor (CAR) Immune Cells | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17622504 | METHODS AND MATERIALS FOR TARGETED EXPANSION OF REGULATORY T CELLS | Final Rejection | The Johns Hopkins University |
| 17764104 | IMMUNOGENIC EGFR PEPTIDE COMPOSITIONS AND THEIR USE IN THE TREATMENT OF CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17617165 | RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNE SIGNALING STATES IN MYELOID MALIGNANCIES VIA THE UBIQUITIN CONJUGATING ENZYME UBE2N | Non-Final OA | CHILDREN'S HOSPITAL MEDICAL CENTER |
| 17420556 | mRNA Vaccine | Final Rejection | eTheRNA Immunotherapies NV |
| 17745307 | TARGETED CHIMERIC PROTEINS AND USES THEREOF | Final Rejection | Universiteit Gent |
| 17442772 | FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L)-BASED CHIMERIC PROTEINS | Non-Final OA | Universiteit Gent |
| 17870024 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CEA AND ANTI-CEA-IL2 IMMUNOCYTOKINES FOR CANCER THERAPY | Non-Final OA | City of Hope |
| 17636470 | ARTIFICIALLY LINKED TANDEM ACYL CARRIER PROTEINS TO ENHANCE FATTY ACID PRODUCTION | Final Rejection | UNIVERSITY OF PUERTO RICO |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy